Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from vTv Therapeutics ( (VTVT) ).
On March 10, 2026, vTv Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on diabetes and other metabolic and immune-related diseases, posted an updated corporate slide presentation highlighting its late-stage pipeline and financial position. The presentation underscores cadisegliatin, a hepatoselective glucokinase activator with FDA Breakthrough designation, as a potential first oral adjunctive therapy for type 1 diabetes in the U.S., targeting a market where roughly 1.5 million patients currently lack such options and about 75% fail to reach American Diabetes Association glycemic targets.
The update details that cadisegliatin has been dosed in more than 500 subjects, has shown positive effects on hypoglycemia and HbA1c in earlier studies, and is now in Phase 3 with completion of CATT1 trial enrollment expected in the third quarter of 2026, signaling a critical upcoming catalyst for the company. vTv also highlights an $88.9 million year-end 2025 cash balance plus an additional $20 million received in February 2026, providing funding runway beyond the anticipated CATT1 topline readout, which, combined with a broader pipeline in immunology, metabolism and oncology, positions the company to pursue both commercial and partnership opportunities in an underserved and growing global type 1 diabetes market.
The materials emphasize the significant unmet need and safety challenges in type 1 diabetes management, particularly the burden of hypoglycemia and the lack of FDA-approved oral adjunctive therapies since the introduction of insulin, framing cadisegliatin’s mechanism as a liver-targeted approach to improving glucose homeostasis. For investors and other stakeholders, the March 2026 presentation serves as both a scientific and strategic update, reinforcing vTv’s focus on late-stage execution in type 1 diabetes while flagging the potential for non-dilutive funding from its other differentiated clinical assets.
The most recent analyst rating on (VTVT) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on vTv Therapeutics stock, see the VTVT Stock Forecast page.
Spark’s Take on VTVT Stock
According to Spark, TipRanks’ AI Analyst, VTVT is a Neutral.
Score is held back primarily by very weak financial performance—minimal revenue, large ongoing losses, and persistent cash burn—despite low debt. Technicals are mixed (longer-term trend above key moving averages but softer near-term momentum), and valuation is constrained by negative earnings. A notable positive is the recent partnership amendment that could provide meaningful non-dilutive funding and milestone/royalty upside.
To see Spark’s full report on VTVT stock, click here.
More about vTv Therapeutics
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases, particularly diabetes, with a deep pipeline spanning immunology, inflammation, metabolism and oncology. Its lead late-stage asset is cadisegliatin, an investigational oral adjunctive therapy targeting the large, underserved type 1 diabetes market, where no oral adjunctive options are currently approved in the U.S.
The company’s strategy centers on advancing cadisegliatin through late-stage trials while leveraging additional clinical-stage assets for potential non-dilutive funding. vTv is led by an experienced executive team in metabolic and diabetes drug development and reported a strong cash position at year-end 2025, bolstered by additional funding in early 2026 to support operations beyond upcoming trial readouts.
The company’s leadership includes a chief scientific officer, chief medical officer, chief commercial officer and other senior executives with biopharma experience. This organizational depth is intended to support both clinical execution and commercialization planning in the competitive diabetes therapeutics market.
Average Trading Volume: 27,007
Technical Sentiment Signal: Buy
Current Market Cap: $152.6M
For an in-depth examination of VTVT stock, go to TipRanks’ Overview page.